Robert W. Baird Downgrades DexCom (NASDAQ:DXCM) to Neutral

Robert W. Baird downgraded shares of DexCom (NASDAQ:DXCM) from an outperform rating to a neutral rating in a research report sent to investors on Friday, Marketbeat.com reports. Robert W. Baird currently has $80.00 price objective on the medical device company’s stock, down from their previous price objective of $161.00.

Other research analysts have also recently issued research reports about the stock. UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a buy rating in a research note on Wednesday, April 10th. Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a buy rating in a research note on Wednesday, April 3rd. StockNews.com cut shares of DexCom from a buy rating to a hold rating in a research note on Monday, June 10th. Stifel Nicolaus dropped their price objective on shares of DexCom from $145.00 to $132.00 and set a buy rating for the company in a report on Friday, July 12th. Finally, Redburn Atlantic began coverage on shares of DexCom in a report on Thursday, May 30th. They set a neutral rating and a $130.00 price objective for the company. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $111.50.

DexCom Stock Up 5.4 %

NASDAQ DXCM opened at $67.48 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The firm has a 50-day simple moving average of $114.02 and a 200 day simple moving average of $123.33. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $27.04 billion, a PE ratio of 43.54, a PEG ratio of 1.58 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the company earned $0.34 earnings per share. The firm’s revenue was up 15.3% on a year-over-year basis. On average, research analysts forecast that DexCom will post 1.76 EPS for the current year.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $85,712.25. Following the completion of the sale, the chief financial officer now owns 84,948 shares of the company’s stock, valued at approximately $9,773,267.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders sold a total of 3,483 shares of company stock valued at $401,450 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

A number of institutional investors have recently bought and sold shares of DXCM. Washington Trust Advisors Inc. grew its holdings in DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares during the period. Inscription Capital LLC bought a new position in shares of DexCom during the fourth quarter worth $248,000. Caprock Group LLC boosted its position in shares of DexCom by 2.2% during the fourth quarter. Caprock Group LLC now owns 17,993 shares of the medical device company’s stock worth $2,233,000 after purchasing an additional 382 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of DexCom by 4.6% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 10,917 shares of the medical device company’s stock worth $1,355,000 after purchasing an additional 483 shares in the last quarter. Finally, Quent Capital LLC boosted its position in shares of DexCom by 11.6% during the fourth quarter. Quent Capital LLC now owns 2,545 shares of the medical device company’s stock worth $316,000 after purchasing an additional 265 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.